Menarini Korea Limited, a wholly owned subsidiary of Italy’s Menarini Group, has struck a deal with UK R&D specialist Futura Medical plc for the exclusive rights to commercialize the latter’s topical, gel-based erectile dysfunction treatment MED3000 in South Korea.
Under the terms of the agreement, Menarini will be responsible for all local MED3000 development, regulatory approvals, product launch and marketing,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?